Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Charles River Laboratories International, Inc. (CRL : NYSE)
 
 • Company Description   
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.

Number of Employees: 20,100

 
 • Price / Volume Information   
Yesterday's Closing Price: $157.12 Daily Weekly Monthly
20 Day Moving Average: 775,982 shares
Shares Outstanding: 49.12 (millions)
Market Capitalization: $7,717.06 (millions)
Beta: 1.49
52 Week High: $254.15
52 Week Low: $91.86
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 8.58% 3.76%
12 Week 57.51% 34.54%
Year To Date -14.89% -20.28%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
251 BALLARDVALE STREET
-
WILMINGTON,MA 01887
USA
ph: 781-222-6000
fax: 978-988-5665
askcharlesriver@crl.com http://www.criver.com
 
 • General Corporate Information   
Officers
James C. Foster - Chairman; President and Chief Executive Officer
Flavia H. Pease - Corporate Executive Vice President and Chief Finan
Michael G. Knell - Corporate Senior Vice President
Nancy C. Andrews - Director
Robert J. Bertolini - Director

Peer Information
Charles River Laboratories International, Inc. (CHCR)
Charles River Laboratories International, Inc. (ESRX)
Charles River Laboratories International, Inc. (MYDP)
Charles River Laboratories International, Inc. (COR)
Charles River Laboratories International, Inc. (GBCS)
Charles River Laboratories International, Inc. (LAXAF)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 159864107
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 49.12
Most Recent Split Date: (:1)
Beta: 1.49
Market Capitalization: $7,717.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $2.37 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $9.62 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 3.07% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 16.33
Trailing 12 Months: 15.12
PEG Ratio: 5.32
Price Ratios
Price/Book: 2.41
Price/Cash Flow: 7.24
Price / Sales: 1.92
EPS Growth
vs. Year Ago Period: 3.08%
vs. Previous Quarter: -12.03%
Sales Growth
vs. Year Ago Period: -2.71%
vs. Previous Quarter: -1.83%
ROE
06/30/25 - -
03/31/25 - 15.19
12/31/24 - 14.69
ROA
06/30/25 - -
03/31/25 - 6.93
12/31/24 - 6.79
Current Ratio
06/30/25 - -
03/31/25 - 1.43
12/31/24 - 1.41
Quick Ratio
06/30/25 - -
03/31/25 - 1.16
12/31/24 - 1.13
Operating Margin
06/30/25 - -
03/31/25 - 13.39
12/31/24 - 13.26
Net Margin
06/30/25 - -
03/31/25 - -0.66
12/31/24 - 0.52
Pre-Tax Margin
06/30/25 - -
03/31/25 - 0.75
12/31/24 - 2.30
Book Value
06/30/25 - -
03/31/25 - 65.15
12/31/24 - 67.80
Inventory Turnover
06/30/25 - -
03/31/25 - 8.67
12/31/24 - 8.20
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.78
12/31/24 - 0.65
Debt-to-Capital
06/30/25 - -
03/31/25 - 44.37
12/31/24 - 39.69
 

Powered by Zacks Investment Research ©